DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/h9dfpb/staphylococcus) has announced the addition of the "Staphylococcus aureus Infections - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Staphylococcus Aureus Infections Overview
- Therapeutics Development
- Pipeline Products for Staphylococcus Aureus Infections- Overview
- Pipeline Products for Staphylococcus Aureus Infections- Comparative Analysis
- Staphylococcus Aureus Infections- Therapeutics under Development by Companies
- Staphylococcus Aureus Infections- Therapeutics under Investigation by Universities/Institutes
- Staphylococcus Aureus Infections- Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Staphylococcus Aureus Infections- Products under Development by Companies
- Staphylococcus Aureus Infections- Products under Investigation by Universities/Institutes
- Staphylococcus Aureus Infections- Companies Involved in Therapeutics Development
For more information visit http://www.researchandmarkets.com/research/h9dfpb/staphylococcus
